Sanofi Deepens Commitment to Neurology with $470 Million Acquisition of Vigil Neuroscience
French pharmaceutical powerhouse Sanofi is making a significant stride in the battle against neurodegenerative diseases with its recent acquisition of Vigil Neuroscience, a U.S.-based biotech firm pioneering innovative therapies for neurological disorders. Announced on May 22, 2025, the deal is valued at approximately €415 million (around $470 million), marking a strategic investment that underlines Sanofi’s … Read more